Platine, Avastin and OLAparib in 1st Line
- Registration Number
- NCT02477644
- Lead Sponsor
- Arcagy Research
- Brief Summary
Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
- Detailed Description
Patients with advanced FIGO stage IIIB - IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 806
I-1. Female Patient must be ≥18 years of age. I-2. Signed informed consent and ability to comply with treatment and follow-up.
I-3. Patient with newly diagnosed I-3-1 Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer,
I-3-2 Histologically confirmed (based on local histopathological findings):
- high grade serous or
- high grade endometrioid or
- other epithelial non mucinous ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation I-3-3 at an advanced stage: FIGO stage IIIB, IIIC, or IV of the 1988 FIGO classification.
I-4. Patient who has completed prior to randomization first line platinum-taxane chemotherapy:
- Platinum-taxane based regimen must have consisted of a minimum of 6 treatment cycles and a maximum of 9. However if platinum based therapy must be discontinued early as a result of non hematological toxicity specifically related to the platinum regimen, (i.e. neurotoxicity, hypersensitivity etc.), patient must have received a minimum of 4 cycles of the platinum regimen.
- Intravenous, intraperitoneal, or neoadjuvant platinum based chemotherapy is allowed; for weekly therapy, three weeks are considered one cycle. Interval debulking is allowed.
I-5. Patient must have received prior to randomization a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of platinum-based chemotherapy. Only in case of interval debulking surgery, it is allowed to realize only 2 cycles of bevacizumab in combination with the last 3 cycles of platinium-based chemotherapy. Bevacizumab treatment should be administered at a dose 15mg/kg q3 weeks up to a total of 15 months.
I-6. Patient must be prior to randomization without evidence of disease (NED) or in complete response (CR) or partial response (PR) from her first line treatment. There should be no clinical evidence of disease progression (physical exam, imagery, CA 125) throughout her first line treatment and prior to study randomization.
I-7. Patient must be randomized at least 3 weeks and no more than 9 weeks after her last dose of chemotherapy (last dose is the day of the last infusion) and all major toxicities from the previous chemotherapy must have resolved to CTC AE grade 1 or better (except alopecia and peripheral neuropathy).
I-8. Patient must have normal organ and bone marrow function:
-
Hemoglobin ≥ 10.0 g/dL.
-
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
-
Platelet count ≥ 100 x 109/L.
-
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).
-
Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN.
-
Serum creatinine ≤ 1.25 x institutional ULN and creatinine clearance > 50 mL/min.
-
Patient not receiving anticoagulant medication who has an International Normalized Ratio (INR) ≤1.5 and an Activated ProThrombin Time (aPTT) ≤1.5 x ULN.
The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or APTT is within therapeutic limits (according to site medical standard). If the patient is on oral anticoagulants, dose has to be stable for at least two weeks at the time of randomization.
-
Urine dipstick for proteinuria < 2+. If urine dipstick i s ≥2+, 24-hour urine must demonstrate <1 g of protein in 24 hours.
-
Normal blood pressure or adequately treated and controlled hypertension (systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg).
I-9. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. I-10. Formalin fixed, paraffin embedded (FFPE) tumor sample from the primary cancer must be available for central BRCA testing and test result must be available for stratification.
I-11. Postmenopausal or evidence of non-childbearing status for women of childbearing potential prior to the first dose of study treatment. (see appendix 4) I-12. For France only: In France, a subject will be eligible for randomization in this study only if either affiliated to, or a beneficiary of, a social security category.
E-1. Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors).
E-2. Ovarian tumors of low malignant potential (e.g. borderline tumors), or mucinous carcinoma.
E-3. Patient with synchronous primary endometrial cancer unless both of the following criteria are met:
- stage < II,
- Less than 60 years old at the time of diagnosis of endometrial cancer with stage IA or IB grade 1 or 2, or stage IA grade III endometrioid adenocarcinoma OR ≥ 60 years old at the time of diagnosis of endometrial cancer with stage IA grade 1 or 2 endometrioid adenocarcinoma.
Patient with serous or clear cell adenocarcinoma or carcinosarcoma of the endometrium is not eligible.
E-4. Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS). Patient with a history of localized malignancy diagnosed over 5 years ago may be eligible provided she completed her adjuvant systemic therapy prior to randomization and that the patient remains free of recurrent or metastatic disease.
Patient with history of primary triple negative breast cancer may be eligible provided she completed her definitive anticancer treatment more than 3 years ago and she remains breast cancer disease free prior to start of study treatment.
E-5. Patient with myelodysplastic syndrome/acute myeloid leukemia history E-6. Patient having experienced for at least one cycle, a delay > 2 weeks due to prolonged hematological recovery during the first line chemotherapy E-7. Patient receiving radiotherapy within 6 weeks prior to study treatment E-8. Major surgery within 4 weeks of starting study treatment and patient must have recovered from any effects of any major surgery E-9. Previous allergenic bone marrow transplant. E-10. Any previous treatment with PARP inhibitor, including olaparib. E-11. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroidal antiemetics).
E-12. Current or recent (within 10 days prior to randomization) chronic use of aspirin > 325 mg/day.
E-13. Concomitant use of known potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir.
E-14. Prior history of hypertensive crisis (CTC-AE grade 4) or hypertensive encephalopathy.
E-15. Clinically significant (e.g. active) cardiovascular disease, including:
- Myocardial infarction or unstable angina within ≤ 6 months of randomization,
- New York Heart Association (NYHA) ≥ grade 2congestive heart failure (CHF).
- Poorly controlled cardiac arrhythmia despite medication (patient with rate controlled atrial fibrillation are eligible), or any clinically significant abnormal finding on resting ECG,
- Peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with activities of daily living [ADL] requiring repair or revision).
E-16. Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or Sub- Arachnoids Hemorrhage (SAH) within 6 months prior to randomization.
E-17. History or evidence of hemorrhagic disorders within 6 months prior to randomization.
E-18. Evidence of bleeding diathesis or significant coagulopathy (in the absence of coagulation).
E-19. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression.
E-20. History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy (e.g. uncontrolled seizures).
E-21. Significant traumatic injury during 4 weeks prior to randomization. E-22. Non-healing wound, active ulcer or bone fracture. Patient with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection is eligible but require 3 weekly wound examinations.
E-23. History of VEGF therapy related abdominal fistula or gastrointestinal perforation or active gastrointestinal bleeding within 6 months prior to the first study treatment.
E-24. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease.
E-25. Patient with evidence of abdominal free air not explained by paracentesis or recent surgical procedure.
E-26. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications.
E-27. Pregnant or lactating women. E-28. Participation in another clinical study with an investigational product during her chemotherapy course immediately prior to randomization.
E-29. Patient unable to swallow orally administered medication and patient with gastrointestinal disorders likely to interfere with absorption of the study medication.
E-30. Patient with a known hypersensitivity to olaparib or any of the recipients of the product.
E-31. Immunocompromised patient, e.g., with known active hepatitis (i.e. Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids or patient who is known to be serologically positive for human immunodeficiency virus (HIV).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Olaparib Olaparib Tablets per os 300 mg Placebo Placebo Tablets per os 300 mg
- Primary Outcome Measures
Name Time Method Efficacy by progression free survival (PFS1) phase up to a total of 15 months
- Secondary Outcome Measures
Name Time Method Overall survival Study end Overall survival is defined as the time from the date of randomization until death due to any cause.
Time to earliest progression by RECIST or CA-125 Study end Time to earliest progression by RECIST v. 1.1 or CA-125 or death is defined as the time from randomization to the earliest date of RECIST or CA-125 progression or death by any cause.
Patient reported outcome 2 years after last patient included Time to start of first subsequent therapy or death (TFST) Study end Time to start of first subsequent therapy or death (TFST) will be assessed. TFST is defined as the time from the date of randomization to the earliest of the date of anti-cancer therapy start date following study treatment discontinuation, or death.
Second Progression Free Survival (PFS2) Study end Time from randomization to second progression is defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the primary variable PFS, or date of death.
Time to start of second subsequent therapy or death (TSST) Study end Time to start of second subsequent therapy or death (TSST) will be assessed. TSST is defined as the time from the date of randomization to the earliest of the date of second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.
Safety and Tolerability Study end
Trial Locations
- Locations (161)
Medical University of Innsbruck
🇦🇹Innsbruck, Austria
Krankenhaus Hietzing
🇦🇹Vienna, Austria
CHU Dinant Godinne
🇧🇪Yvoir, Belgium
Hyogo Cancer Center
🇯🇵Hyogo, Japan
National Cancer Center Hospital
🇯🇵Tokyo, Japan
Hopital Tenon
🇫🇷Paris, France
Hôpital de la Citadelle
🇧🇪Liège, Belgium
Kuopio University Hospital
🇫🇮Kuopio, Finland
Institut Jules Bordet
🇧🇪Bruxelles, Belgium
Centre François Baclesse
🇫🇷Caen, France
Hôpital Cochin
🇫🇷Paris, France
Landeskrankenhaus Salzburg
🇦🇹Salzburg, Austria
UZ Gasthuisberg
🇧🇪Leuven, Belgium
Oulu University Hospital
🇫🇮Oulu, Finland
Hôpital Jean Minjoz
🇫🇷Besancon, France
KH der Barmherzigen Brüder Graz
🇦🇹Graz, Austria
Medical University of Graz
🇦🇹Graz, Austria
Antwerp University Hospital
🇧🇪Edegem, Belgium
Clinique et maternité Sainte Elisabeth
🇧🇪Namur, Belgium
Turku University Hospital
🇫🇮Turku, Finland
Groupe Hospitalier Saint-Joseph
🇫🇷Paris, France
Medical University of Vienna
🇦🇹Vienna, Austria
Hôpital Michallon - Centre Hospitalier Universitaire de Grenoble
🇫🇷La Tronche, France
Centre Azuréen de Cancérologie
🇫🇷Mougins, France
Hôpital de Mont-de-Marsan
🇫🇷Mont-de-marsan, France
Hôpital Européen Georges Pompidou
🇫🇷Paris, Ilhe De France, France
Hochtaunus-Kliniken
🇩🇪Bad Homburg, Germany
Onkologie Bottrop
🇩🇪Bottrop, Germany
Städtisches Klinikum Dessau
🇩🇪Dessau, Germany
Centre Antoine Lacassagne
🇫🇷Nice, France
Albertinen Krankenhaus
🇩🇪Hamburg, Germany
Klinkum Gütersloh
🇩🇪Gütersloh, Germany
Universitätsklinikum Halle
🇩🇪Halle, Germany
Universitätsklinikum Carl Gustav Carus
🇩🇪Dresden, Germany
Johannes Wesling Klinikum
🇩🇪Minden, Germany
Centre Hospitalier Lyon Sud
🇫🇷Pierre-benite, France
Centre Eugène Marquis
🇫🇷Rennes, France
Klinikum Frankfurt Höchst
🇩🇪Frankfurt, Germany
Institut Claudius Regaud
🇫🇷Toulouse, France
Universitätsklinikum Düsseldorf
🇩🇪Düsseldorf, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Istituto Nazionale Tumori - IRCCS Pascale
🇮🇹Napoli, Italy
Ospedale Santa Maria della Misericordia
🇮🇹Perugia, Italy
Hôpital René Huguenin, Institut Curie
🇫🇷Saint-cloud, France
Centre de Radiothérapie - Clinique Sainte-Anne
🇫🇷Strasbourg, France
Charité - Universitätsmedizin Berlin (CVK)
🇩🇪Berlin, Germany
GYNAEKOLOGICUM Bremen
🇩🇪Bremen, Germany
Evangelisches Krankenhaus Düsseldorf
🇩🇪Düsseldorf, Germany
Klinikum Aschaffenburg
🇩🇪Aschaffenburg, Germany
Ospedale Senatore Antonio Perrino
🇮🇹Brindisi, Italy
Istituto Nazionale Tumori
🇮🇹Milano, Italy
Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Universitätsklinikum Gießen und Marburg
🇩🇪Marburg, Germany
Universitätsfrauenklinik Erlangen
🇩🇪Erlangen, Germany
Klinikum Esslingen
🇩🇪Esslingen, Germany
St. Vincentius Kliniken
🇩🇪Karlsruhe, Germany
Klinikum der Universität München
🇩🇪München, Germany
Universitätsfrauenklinik Regensburg
🇩🇪Regensburg, Germany
ROMed Klinikum Rosenheim
🇩🇪Rosenheim, Germany
H. U. Fundación Alcorcón
🇪🇸Alcorcón, Spain
Policlinico S.Orsola-Malpighi
🇮🇹Bologna, Italy
Spedali Civili-Università di Brescia
🇮🇹Brescia, Italy
Linköping University Hospital
🇸🇪Linköping, Sweden
Ospedale Mauriziano
🇮🇹Torino, Italy
H. U. Miguel Servet
🇪🇸Zaragoza, Spain
H. General Universitario de Valencia
🇪🇸Valencia, Spain
Jichi Medical University Hospital
🇯🇵Tochigi, Japan
Ospedale S. Anna
🇮🇹Torino, Italy
H.U. Arnau de Vilanova
🇪🇸Lleida, Spain
University of Tsukuba Hospital
🇯🇵Ibaraki, Japan
Institut Gustave Roussy
🇫🇷Villejuif, France
Rigshospitalet
🇩🇰Copenhagen, Denmark
Herlev Hospital
🇩🇰Herlev, Denmark
ICO Paul Papin
🇫🇷Angers, France
Institut Sainte-Catherine
🇫🇷Avignon, France
Centre Jean Perrin
🇫🇷Clermont-ferrand, France
Centre Georges François Leclerc
🇫🇷Dijon, France
Centre Jean Bernard - Clinique Victor Hugo
🇫🇷Le Mans, France
Centre Léon Bérard
🇫🇷Lyon, France
Hôpital des Diaconesses
🇫🇷Paris, France
Praxisklinik Krebsheilkunde für Frauen
🇩🇪Berlin, Germany
Klinikum der Johann Wolfgang Goethe-Universität
🇩🇪Frankfurt, Germany
Universitätsfrauenklinik Freiburg
🇩🇪Freiburg, Germany
Universitäts-Frauenklinik Göttingen
🇩🇪Göttingen, Germany
Universitätsmedizin Greifswald
🇩🇪Greifswald, Germany
Gynäkologisch-Onkologische Praxis Hannover
🇩🇪Hannover, Germany
Universitätsfrauenklinik Köln
🇩🇪Köln, Germany
HELIOS Klinikum Krefeld
🇩🇪Krefeld, Germany
Klinikum Ludwigsburg
🇩🇪Ludwigsburg, Germany
Robert-Bosch-Krankenhaus
🇩🇪Stuttgart, Germany
Universitätsklinikum Ulm
🇩🇪Ulm, Germany
Marien Hospital Witten
🇩🇪Witten, Germany
AO ASL 4 - Ospedale di Prato
🇮🇹Prato, Italy
Kagoshima University Medical And Dental Hospital
🇯🇵Kagoshima, Japan
Saitama Medical University International Medical Center
🇯🇵Saitama, Japan
Centre Hospitalier Princesse Grace
🇲🇨Monaco, Monaco
H. de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
H. U. Reina Sofía
🇪🇸Córdoba, Spain
Centro Riferimento Oncologico
🇮🇹Aviano, Italy
EO Ospedali Galliera
🇮🇹Genova, Italy
Ospedale San Luca
🇮🇹Lucca, Italy
Istituto Oncologico Veneto
🇮🇹Padova, Italy
Ospedale Santa Chiara
🇮🇹Trento, Italy
Arcispedale S. M. Nuova
🇮🇹Reggio Emilia, Italy
Istituto Regina Elena
🇮🇹Roma, Italy
Policlinico Umberto I La Sapienza
🇮🇹Roma, Italy
Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore
🇮🇹Roma, Italy
Institut Bergonié
🇫🇷Bordeaux, France
Polyclinique Bordeaux Nord
🇫🇷Bordeaux, France
Groupe Hospitalier Mutualiste de Grenoble
🇫🇷Grenoble, France
Centre Hospitalier Départemental Les Oudairies
🇫🇷La Roche-sur-yon, France
Centre Hospitalier Régional Universitaire de Lille - Hôpital Huriez
🇫🇷Lille, France
Centre Oscar Lambret
🇫🇷Lille, France
Institut Paoli Calmettes
🇫🇷Marseille, France
ICM Val d'Aurelle
🇫🇷Montpellier, France
Centre Catherine de Sienne - Group confluent
🇫🇷Nantes, France
Centre Hospitalier Régional d'Orléans
🇫🇷Orleans, France
Clinique Francheville
🇫🇷Perigueux, France
Institut Curie - Hopital Claudius Régaud
🇫🇷Paris, France
Centre CARIO - HPCA
🇫🇷Plérin, France
Hôpital de la Milétrie - CHU de Poitiers - Pôle Régional de Cancérologie
🇫🇷Poitiers, France
Centre Henri Becquerel
🇫🇷Rouen, France
ICO Centre René Gauducheau
🇫🇷Saint-herblain, France
Centre Paul Strauss
🇫🇷Strasbourg, France
Hôpitaux Universitaires de Strasbourg
🇫🇷Strasbourg, France
Clinique Pasteur - ONCOSUD
🇫🇷Toulouse, France
ICL Institut de Cancérologie de Lorraine
🇫🇷Vandoeuvre-les-nancy, France
MD Anderson Cancer Center Madrid
🇪🇸Madrid, Spain
C.S. Parc Taulí
🇪🇸Barcelona, Spain
H. U. Ramón y Cajal
🇪🇸Madrid, Spain
H. U. P. La Fe
🇪🇸Valencia, Spain
Complejo Hospitalario de Navarra
🇪🇸Pamplona, Spain
Instituto Valenciano de Oncología
🇪🇸València, Spain
Klinikum Augsburg
🇩🇪Augsburg, Germany
Kliniken Essen Mitte
🇩🇪Essen, Germany
HELIOS Klinikum Berlin-Buch
🇩🇪Berlin, Germany
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Universitätsklinikum Hamburg-Eppendorf
🇩🇪Hamburg, Germany
Universitätsklinikum Jena
🇩🇪Jena, Germany
Klinikum Kassel
🇩🇪Kassel, Germany
Sana Klinikum Offenbach
🇩🇪Offenbach, Germany
Ortenau Klinikum
🇩🇪Offenburg, Germany
Onkologie Ravensburg
🇩🇪Ravensburg, Germany
Kliniken des Landkreises Neumarkt
🇩🇪Neumarkt, Germany
Klinikum am Steinenberg
🇩🇪Reutlingen, Germany
Klinikum Südstadt
🇩🇪Rostock, Germany
Universitäts-Frauenklinik Tübingen
🇩🇪Tübingen, Germany
Klinikum Worms
🇩🇪Worms, Germany
St. Elisabeth Krankenhaus
🇩🇪Köln, Germany
Universitätsklinikum Schleswig-Holstein
🇩🇪Lübeck, Germany
Universitätsklinikum Essen
🇩🇪Essen, Germany
Universitätsklinikum Münster
🇩🇪Münster, Germany
amO Wolfsburg
🇩🇪Wolfsburg, Germany
Klinikum Konstanz
🇩🇪Konstanz, Germany
H.U. Central de Asturias
🇪🇸Oviedo, Spain
Klinikum rechts der Isar
🇩🇪München, Germany
H. U. 12 de Octubre
🇪🇸Madrid, Spain
HELIOS Dr. Horst Schmidt Kliniken
🇩🇪Wiesbaden, Germany
Universitätsklinikum Würzburg
🇩🇪Würzburg, Germany
Tampere University Hospital
🇫🇮Tampere, Finland
Ehime University Hospital
🇯🇵Ehime, Japan